What Changed at Subtle Medical

Every material change AI Health Index has tracked at Subtle Medical: new modules, model and architecture updates, clinical evidence, regulatory status, security certifications, and integration depth. Each entry states what changed, cites its source, and carries our read on what it means for a buyer. The graded assessment of this vendor across all fifteen capability axes sits on its index profile.

Funding rounds, valuations, and awards are not product changes and are not logged here. Acquisitions appear only where there is direct product impact.

Impact
Type
1 entry
Showing changes for Subtle Medical only.Show the full log

May 2026

S
Subtle Medical
May 27, 2026
MediumVerified
Regulatory / FDA

Subtle Medical received FDA clearance for SubtleHD (PET), a next generation AI PET image enhancement product for PET/CT and PET/MR systems. The company states it supports all FDA approved radiotracers, enables up to 75 percent faster PET imaging on existing scanners, improves SUVmax quantitation accuracy, allows radiologist adjustable denoising levels, and incorporates anatomical CT data into reconstruction. It extends prior clearances covering SubtlePET and SubtleHD (MR).

Our read

PET scanner capacity is a hard constraint for most imaging programs, and acquisition acceleration is one of the few levers that adds throughput without capital equipment. The material detail for buyers is radiotracer compatibility: support across all FDA approved radiotracers, rather than 18F-FDG alone, is what makes this usable in theranostics and advanced molecular imaging programs where the older generation was limited. Two caveats worth carrying into procurement: the acceleration figure is a vendor claim and should be validated against your own protocols and reader acceptance, and adjustable denoising means image appearance becomes a configurable parameter, which needs a documented standard rather than per radiologist preference drift.

Related axis: FDA and Regulatory StatusTrade pressView source